RXII vs. AGRX, ATXI, ARAV, VRPX, NBY, BPTSY, PHIO, BPTS, ARDS, and GOVX
Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include Agile Therapeutics (AGRX), Avenue Therapeutics (ATXI), Aravive (ARAV), Virpax Pharmaceuticals (VRPX), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Phio Pharmaceuticals (PHIO), Biophytis (BPTS), Aridis Pharmaceuticals (ARDS), and GeoVax Labs (GOVX). These companies are all part of the "medical" sector.
RXi Pharmaceuticals (NASDAQ:RXII) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.
RXi Pharmaceuticals has higher earnings, but lower revenue than Agile Therapeutics. RXi Pharmaceuticals is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Agile Therapeutics had 1 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 1 mentions for Agile Therapeutics and 0 mentions for RXi Pharmaceuticals. RXi Pharmaceuticals' average media sentiment score of 0.00 equaled Agile Therapeutics'average media sentiment score.
Agile Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 1,999.80%. Given Agile Therapeutics' higher possible upside, analysts plainly believe Agile Therapeutics is more favorable than RXi Pharmaceuticals.
RXi Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Agile Therapeutics received 232 more outperform votes than RXi Pharmaceuticals when rated by MarketBeat users. However, 68.09% of users gave RXi Pharmaceuticals an outperform vote while only 67.62% of users gave Agile Therapeutics an outperform vote.
Agile Therapeutics has a net margin of -73.83% compared to RXi Pharmaceuticals' net margin of -4,990.20%. Agile Therapeutics' return on equity of 0.00% beat RXi Pharmaceuticals' return on equity.
9.6% of RXi Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are owned by institutional investors. 1.0% of RXi Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Agile Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Agile Therapeutics beats RXi Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get RXi Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RXi Pharmaceuticals Competitors List
Related Companies and Tools
